New Investigator Grant Awarded to Rebecca Ronsley

DIPG and DMG are devastating brain tumors that tragically take the lives of children and young adults, and finding an effective treatment is an urgent challenge. At our institution, we are leading groundbreaking research to fight these tumors using the power of the immune system. Our innovative therapy, called CAR T-cell therapy, is like giving the body’s immune cells a high-tech upgrade to specifically target and attack the tumor. We’re testing a unique version “quad- CAR T cell product” that focuses on four key proteins to better combat these cancers.

In this exciting clinical trial, we’re also gathering cerebrospinal fluid (CSF)—a liquid surrounding the brain and spine—before and after the treatment. By studying these samples, we can uncover clues about how the
tumors respond to therapy and identify potential side effects. This knowledge will help us fine-tune the treatment and improve its effectiveness. This project is already underway, with samples being collected and a team of experts analyzing them. With strong progress and a clear plan, we are confident this research will yield critical insights in just three years. Most importantly, it aligns with the ChadTough Defeat DIPG Foundation’s vision of a future where no child or young adult has to face these devastating diseases. Together, we are taking a bold step toward that goal!